Aflibercept-Mrbb Suppliers & Bulk Manufacturers
Available Forms: Intravitreal injection (liquid solution)
Available Strengths: 2mg (0.05 mL of a 40 mg/mL solution)
Reference Brands: Eylea(US & EU); Ahzantive - biosimilar to biosimilar to Eylea
Category: Biosimilars
Ahzantive, a biosimilar of Eylea, inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. It effectively treats age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Benefits include similar efficacy, potentially lower costs, and improved access to crucial eye disease therapies.
Product Description:
Ahzantive, a biosimilar of Eylea, is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality in compliance with GMP and MDR standards. In the US, FDA approval involves extensive clinical validation, safety assessments, and comparability data. In the EU, CE marking certifies conformity with MDR standards for biosimilars. These products undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical results, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, effective ophthalmic biosimilars supporting eye disease management worldwide.
Aflibercept-Mrbb — third party manufacturing & bulk supply
Aflibercept-Mrbb is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Aflibercept-Mrbb is supplied as Intravitreal injection (liquid solution) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Aflibercept-Mrbb listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Aflibercept-Mrbb →Frequently Asked Questions
Aflibercept‑mrbb is used to treat eye conditions caused by abnormal blood vessel growth and fluid leakage in the retina, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It works by inhibiting vascular endothelial growth factor (VEGF) to slow vision loss and improve retinal health.
The active ingredient is aflibercept, a recombinant fusion protein that binds VEGF-A, VEGF-B, and placental growth factor (PlGF). It is formulated as a sterile solution for intravitreal injection.
The trade name is Aflibercept‑mrbb.
Aflibercept‑mrbb is manufactured by licensed biopharmaceutical companies producing approved biosimilars according to regulatory standards.
The generic name is Aflibercept.
The brand name is Aflibercept‑mrbb.
It is manufactured in GMP-certified biopharmaceutical facilities, ensuring sterility, quality, and compliance for intravitreal use.
Related Products
Ustekinumab‑Aauz
Strength:
45 mg or 90 mg
Form: Subcutaneous injection, Intravenous infusion
Reference Brands: Stelara(US & EU); Otulfi (ustekinumab-srlf) is a biosimilar of Stelara
View Details
Aflibercept‑Ayyh
Strength:
2 mg/0.05 mL
Form: Intravitreal injection (liquid solution)
Reference Brands: Eylea(US & EU); Pavblu - biosimilar to biosimilar to Eylea
View Details
Ustekinumab‑Srlf
Strength:
45 mg or 90 mg doses
Form: Subcutaneous injection, Intravenous infusion
Reference Brands: Stelara(US & EU); Imuldosa (ustekinumab-srlf) is a biosimilar of Stelara
View Details
Ustekinumab‑Aekn
Strength:
Intravenous Infusion(130 mg/26 mL), Subcutaneous injection (pre-filled syringes, pens)
Form: Subcutaneous injection (pre-filled syringes, pens); Intravenous Infusion
Reference Brands: Stelara(US & EU); Selarsdi- biosimilar of Stelara
View Details
Omalizumab‑Igec
Strength:
75 mg/0.5 mL and 150 mg/mL
Form: Pre filled syringe
Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair
View Details
Eculizumab‑Aeeb
Strength:
300 mg/20 mL (IV infusion),
Form: Injection for intravenous infusion
Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris
View Details
Insulin‑Aspart‑Szjj
Strength:
100 units/mL
Form: SQ Injection
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
View DetailsQuick Response Guaranteed | Verified Suppliers
